Effects of acute and long-term typical or atypical neuroleptics on morphine-induced behavioural effects in mice.
1. It has been suggested that the high prevalence of drug abuse in schizophrenics is related to chronic treatment with typical neuroleptics and dopaminergic supersensitivity that develops as a consequence. Within this context, atypical neuroleptics do not seem to induce this phenomenon. In the present study, we investigated the effects of acute administration or withdrawal from long-term administration of haloperidol and/or ziprasidone on morphine-induced open-field behaviour in mice. 2. In the first experiment, mice were given a single injection of haloperidol (1 mg/kg, i.p.) or several doses of ziprasidone (2, 4 or 6 mg/kg, i.p.) and motor activity was quantified by the open-field test. The aim of the second experiment was to verify the effects of an acute injection of haloperidol (1 mg/kg) or ziprasidone (6 mg/kg) on 20 mg/kg morphine-induced behaviours in the open-field test. In the third experiment, mice were treated with 1 mg/kg haloperidol and/or 2, 4 or 6 mg/kg ziprasidone for 20 days. Seventy-two hours after the last injection, mice were injected with 20 mg/kg, i.p., morphine and then subjected to the open-field test. Acute haloperidol or ziprasidone decreased spontaneous general activity and abolished morphine-induced locomotor stimulation. 3. Withdrawal from haloperidol or ziprasidone did not modify morphine-elicited behaviours in the open-field test. The results suggest that withdrawal from neuroleptic treatments does not contribute to the acute effect of morphine in schizophrenic patients.
Department of Pharmacology, São Paulo Federal University, São Paulo, Brazil.
André W
AW
Hollais
Camilla L
CL
Patti
Karina A
KA
Zanin
Daniela F
DF
Fukushiro
Laís F
LF
Berro
Rita C
RC
Carvalho
Sonia R
SR
Kameda
Roberto
R
Frussa-Filho
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D051379:Mice; D009020:Morphine / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy; D013844:Thiazoles / Q000494:pharmacology
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone; D009020:Morphine; D006220:Haloperidol
dopamine; haloperidol; hyperactivity; mor-phine; open-field; ziprasidone